Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000247

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration. Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.

            Lead Product(s): Albendazole

            Therapeutic Area: Infections and Infectious Diseases Product Name: Albendazole-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2021

            Post Enquiry
            POST ENQUIRY